Renovaro Biosciences
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $181 | $0 | $0 |
Gross Profit | 90 | -33 | |
EBITDA | -43,929 | -4,220 | |
EBIT | -43,961 | -4,254 | |
Net Income | -44,212 | -17,024 | -4,529 |
Net Change In Cash | 181 | 0 | 0 |
Free Cash Flow | -2,016 | -2,639 | -3,188 |
Cash | 220 | 312 | 243 |
Basic Shares | 156,567 | 147,488 | 65,852 |
Annual Financials
| Values in thousands | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -113 | -123 | -391 |
EBITDA | -19,483 | -22,702 | -23,278 |
EBIT | -19,596 | -22,826 | -23,401 |
Net Income | -39,684 | -113,433 | -26,723 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -11,804 | -15,737 | -20,659 |
Cash | 1,874 | 9,172 | 20,664 |
Basic Shares | 56,265 | 52,528 | 47,167 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.28 |
2024-06-30 | -$0.10 |
2024-03-31 | -$0.15 |
2023-12-31 | -$0.06 |
